Klein Eric A
Section of Urologic Oncology, Glickman Urological Institute, Cleveland, OH 44195, USA.
Crit Rev Oncol Hematol. 2005 Apr;54(1):1-10. doi: 10.1016/j.critrevonc.2004.11.008.
Prostate cancer is an attractive target for chemoprevention because of its ubiquity, treatment-related morbidity, long latency between premalignant lesions and clinically evident cancer, and defined molecular pathogenesis. Prevention of this disease would have a major impact on disease-associated cost, morbidity, and mortality for a large segment of the population. A major advance in prevention of prostate cancer came in 2003 with the publication of the Prostate Cancer Prevention Trial (PCPT). This overview summarizes the results of that trial, the design of other large-scale trials, and advances in understanding of the molecular mechanisms underlying the effect of other promising agents, including dutasteride, selenium, Vitamin E, Vitamin D, COX-2 inhibitors, lycopene, and green tea.
前列腺癌是化学预防的一个有吸引力的靶点，因为它普遍存在、与治疗相关的发病率、癌前病变与临床明显癌症之间的潜伏期长，以及明确的分子发病机制。预防这种疾病将对很大一部分人群的疾病相关成本、发病率和死亡率产生重大影响。2003年，随着前列腺癌预防试验（PCPT）结果的发表，前列腺癌预防取得了重大进展。本综述总结了该试验的结果、其他大规模试验的设计，以及对其他有前景的药物（包括度他雄胺、硒、维生素E、维生素D、COX-2抑制剂、番茄红素和绿茶）作用的分子机制的理解进展。
